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Animal ruleThe efficacy of plazomicin for pneumonic plague was evaluated in a non-human primate model. African
Green monkeys challenged with a lethal aerosol of Yersinia pestis [median (range) of 98 (15–331) LD50s]
received placebo (n = 12) or ‘humanized’ dose regimens (6.25, 12.5 or 25 mg/kg every 24 h) of plazomicin
(n = 52) after the onset of fever for a duration of 5 or 10 days. All animals treated with placebo died, while
36 plazomicin-treated animals survived through study end. The majority (33/36) were either in the
10-day (high-/mid-/low-dose) or 5-day high-dose groups. The findings suggest an exposure range of
plazomicin for treatment of pneumonic/bacteremic Y. pestis infection in humans.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Plazomicin (plazomicin sulfate) is a novel compound in the
aminoglycoside class of antibiotics that is being developed for
the treatment of serious Gram-negative infections. Plazomicin con-
tains structural modifications that allow it to maintain activity in
the presence of the common aminoglycoside-modifying enzymes
(AMEs) that inactivate currently marketed aminoglycosides1
(Fig. 1). Furthermore, plazomicin has demonstrated in vitro activity
against clinical isolates that possess a broad range of resistance
mechanisms, including beta-lactamases and fluoroquinolone tar-
get site mutations that limit the utility of other classes of antibi-
otics. At the time of this publication, plazomicin is being studied
in two phase 3 clinical trials (NCT01970371 and NCT02486627),
one of which is specifically focused on serious infections due to
carbapenem-resistant Enterobacteriaceae (CRE), a family of
multidrug resistant (MDR) pathogens that has been identified as
an urgent health need.2
In partnership with the Biomedical Advanced Research and
Development Authority (BARDA), plazomicin is also being
investigated for the treatment of two diseases caused by potentialbioterrorism agents, pneumonic Tularemia, caused by Franciscella
tularensis, and pneumonic plague, caused by Yersinia pestis. In this
article, we describe the evaluation of plazomicin in a primate
model of pneumonic plague.
Y. pestis is considered to be one of the most threatening biowea-
pons due to the virulence of the bacterium, the availability of vir-
ulent strains in natural environmental reservoirs, the ease of
preparation of aerosols and the rapid onset of symptoms and death
associated with primary pneumonic plague.3 Also, unlike diseases
such as anthrax, pneumonic plague has a greater potential to
spread from person-to-person.3,4 While a handful of plague cases
are reported annually in the United States, they are predominantly
the bubonic form, which is generally caused by contact with an
infected animal.5 The severity of disease and high associated mor-
tality of primary pneumonic plague is not adequately captured in
these bubonic plague patients. The sparse case reports of primary
pneumonic plague that are available in the literature indicate that
it is a rapidly progressing and most often lethal disease, even with
antibiotic treatment.3 While it is fortunate that the incidence of
pneumonic plague is low, there is a critical need for new therapies
in the event of an attack with weaponized, aerosolized plague.
Levofloxacin and moxifloxacin are the only two FDA-approved
antibiotics for the treatment of primary pneumonic plague. Both
were recently approved (2012 and 2015 respectively) using an
animal model similar to the one described in this study.6,7 While
AAC(6’)
6’
ANT(4’,4’’)
4’ 3’ 2”
APH(3’) AAC(2’)
ANT(2’’)
APH(2’’)
AAC(3)
Figure 1. Plazomicin structure and AME families from Gram-negative and Gram-
positive organisms. AME families shown with dotted arrows cannot modify
plazomicin. AAC, aminoglycoside acetyltransferase; ANT, aminoglycoside
nucleotidyltransferase; APH, aminoglycoside phosphotransferase.
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both are members of the fluoroquinolone class of antibiotics and
therefore share common resistance mechanisms. In the event that
a fluoroquinolone-resistant strain was disseminated, either natu-
rally or intentionally, the efficacy of both approved drugs would
be compromised. The ideal armamentarium for any infectious
agent would consist of several drugs possessing different modes
of action. Plazomicin is an aminoglycoside antibiotic that targets
the bacterial ribosome and therefore has a different cellular target
and mechanism of bacterial killing than the fluoroquinolones.
Plazomicin has also been chemically modified to maintain activity
in the presence of many of the AMEs that inactivate older amino-
glycosides (Fig. 1).1 Based on its differential mode of action com-
pared with the fluoroquinolones and its ability to kill strains
resistant to other members of the aminoglycoside class, pla-
zomicin would significantly add to our armamentarium against
Y. pestis.
The United States Food and Drug Administration’s (FDA) ‘animal
rule’ enables a path to regulatory approval for new therapies direc-
ted at rare infectious agents by establishing efficacy in animals
when the study drug cannot be feasibly/ethically tested in
humans.8 Therefore this study aimed to test the hypothesis that
plazomicin could improve the survival of non-human primates
after a lethal aerosol dose of Y. pestis strain Colorado 92.9 The Afri-
can Green monkey (AGM) was chosen as the test system predom-
inately due to historical precedent. AGMs are highly susceptible to
Y. pestis aerosol infection and the timing and evolution of dissem-
inated disease following aerosol exposure is similar to humans.10
AGM was the primate species utilized in the levofloxacin and mox-
ifloxacin studies to support approval,6,7 and the FDA advisory com-
mittee from the levofloxacin approval unanimously agreed the
model is able to ‘provide substantial evidence of efficacy. . .for the
treatment of humans with pneumonic plague’.11,12
In addition, an important feature of this study is that treatment
with plazomicin was delayed until the disease advanced from a
primary pneumonia to a systemic disease hallmarked by spread
of Y. pestis from the lungs into the bloodstream and surrounding
organs, a process that takes between 2 and 3 days. In the event
of an outbreak or intentional release of aerosolized plague, it is
likely that many exposed individuals will not present to a medical
facility for treatment until they exhibit clear signs and symptoms
of infection. We therefore sought to evaluate the efficacy of pla-
zomicin under these more challenging conditions in which the dis-
ease has already progressed.
The current phase 3 plazomicin studies are using a once-daily
15 mg/kg dose, administered as a 30-min intravenous (IV) infusion,
with dose adjustments required for patients with compromisedrenal function.13 Based on a population PK model generated from
healthy volunteer data and data collected in patients with compli-
cated urinary tract infections or acute pyelonephritis, the mean
daily steady state area under the curve (AUC24) associated with
this dose is 262 mg/L  h.14 We sought to determine if this AUC24
was sufficient to treat pneumonic plague in AGMs.
We also investigated the impact of duration of plazomicin ther-
apy on outcome. There are very few antibiotic studies that examine
the optimal duration of therapy and, as a result, one of the biggest
knowledge gaps in the antibacterial field is a clear understanding
of the importance of treatment duration on outcome.15–17 The
AGM study provides an opportunity to empirically examine the
impact of treatment duration on outcomes in otherwise healthy
animals with a life-threatening, multi-organ infection with a large
bacterial burden when therapy is initiated, akin to the disease state
in critically ill patients with pneumonia and associated bac-
teremia/sepsis.2. Material and methods
2.1. Overview of plague study design
Plazomicin was evaluated in three separate studies referred to
below as FY-105A, FY-105B and FY-036A. These studies were sim-
ilar in design but each explored different aspects of plazomicin
dosing and duration of therapy. Due to animal handling limita-
tions, each study was separated into two exposure cohorts. In total,
64 animals were evaluated across the six cohorts. A placebo group
was included in each cohort and all attempts were made to ensure
that each cohort was handled identically. Briefly, AGMs were anes-
thetized and exposed, head only, via aerosol to lethal doses of Y.
pestis. Treatment was delayed until the disease had progressed
from an isolated pneumonia to a multi-organ, systemic disease
marked by spreading of the bacteria through the bloodstream to
other body sites and the occurrence of sustained fever. Since our
intent was to treat animals when they were bacteremic, and know-
ing that the presence of bacteremia takes >24 h to confirm, we
required a surrogate marker. It had previously been established
that the systemic phase of disease is associated with fever.10 There-
fore, animals were continuously monitored for development of
fever via implanted telemetry. Treatment with placebo or ‘human-
ized’ doses of plazomicin (6.25, 12.5 or 25 mg/kg 30-min infusion
every 24 h) was initiated within 6 h of onset of sustained fever
and was continued for 5 or 10 days, depending on the study cohort.
The total observation period post-aerosol challenge was between
28 and 30 days (Fig. 2). Blood samples were taken to evaluate pla-
zomicin PK on the first, third and last day of treatment and com-
pared with results from healthy animals. In addition, blood was
sampled pre-challenge and at time of death or study end, to eval-
uate serum chemistry, hematology and quantitative bacteriology.
Upon death, euthanasia due to meeting moribund criteria, or
euthanasia due to study end, histopathological examination of
multiple organs and determination of bacterial burden were
performed.2.2. Animal assurance and procedures
All studies complied with all applicable sections of the Final
Rules of the Animal Welfare Act regulations (9 CFR Parts 1, 2 and
3) and the Guide for the Care and Use of Laboratory Animals (8th
Ed., 2010, National Academies Press, Washington, DC). All in-life
portions of the studies were performed in Lovelace Respiratory
Research Institutes (LRRI) facilities, which are fully accredited by
the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC).
Day 0 Day 2-3 Day 28-30
Euthanasia and test for 
bacterial loadFever detected/ treatment start
Infect (Aerosol 
exposure)
Daily observaons, periodic blood draws for 
clinical chemistry, hematology, 
pharmacokinecs
Figure 2. Study timeline overview.
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and chair and limb restraints. Animals were quarantined for at
least 30 days prior to study acceptance, and only animals of accept-
able health were included. Prior to challenge group allocation, each
animal underwent a complete physical examination by a staff vet-
erinarian or veterinary technician under the supervision of a vet-
erinarian. The examination included complete blood count,
serum chemistry and fecal ova and parasite determination. Addi-
tionally, AGMs were screened prior to arrival at LRRI for tuberculo-
sis, measles, simian immunodeficiency virus, simian T-cell
leukemia virus, simian retro virus (SRV1, 2, 3, 4, D) and simian
agent 8.
T34 telemeters (Konigsberg Instruments, Inc., Pasadena, CA)
were secured to the abdominal wall within the peritoneum for
continuous monitoring of body temperature, respiratory rate and
heart rate. All animals also had a venous access catheter aseptically
implanted into the right femoral vein and tunneled through the
right flank and back, emerging through the skin of the upper
mid-back. Catheters were maintained per LLRI’s standard proce-
dures for indwelling vascular catheter care and maintenance in
nonhuman primates. Animals were moved into the ABSL-3 facility
at least 5 days prior to challenge with Y. pestis.
2.3. Bacterial challenge
Y. pestis Colorado 92 was obtained from the Centers for Disease
Control and Prevention (CDC, Fort Collins, CO) via C. Rick Lyons
(School of Medicine, University of New Mexico, Albuquerque,
NM) and characterized in the LRRI Animal Biosafety Level (ABSL)-
3 microbiology laboratory. Seed and working bacterial stocks were
stored frozen (70 to 90 C). Y. pestis Colorado 92 nebulizer sus-
pensions were prepared fresh on each exposure day. A single work-
ing stock vial was removed from frozen storage and used to
inoculate tryptose blood agar base (TBAB) slants. The TBAB slants
were incubated at 28 C ± 2 C for 72 h. Phenotype was verified
on Congo Red agar. After incubation, cells from the TBAB slants
were suspended into 2 mL of 1% peptone per slant. The bacterial
suspensions were collected into a 50 mL conical tube and then cen-
trifuged at 4100 rpm ± 200 rpm, 4 C ± 2 C for 20 min. The Y. pestis
pellet was suspended in 4 mL of 1% peptone and mixed using a vor-
tex mixer. The optical density at 600 nm (OD600) was determined
and the culture adjusted to the target density.
Animals were fasted overnight and anesthetized by intramus-
cular injection of 2–6 mg/kg Telazol. The exposure system was a
Class 3 biosafety glovebox with a head-only exposure unit and
plethysmography measuring respiratory frequency, tidal volume
and minute volume during the exposure. The bacterial suspension
was nebulized using a Collison MRE-3 (MRE-3 jet, BGI, Inc., Wal-
tham, MA) nebulizer and delivered to the anesthetized animal
which was breathing freely. The concentration of the bacteria inthe nebulizer suspension was estimated (by OD600) and set to
deliver a target concentration of bacteria per minute with the goal
of achieving an infectious load in the lungs of approximately
35,000 ± 17,500 colony forming units (CFUs) of Y. pestis which
equates to 100 ± 50 times the median lethal dose (LD50).18
The bacteria-containing aerosol was sampled directly into an all
glass impinger (AGI; Ace Glass, Inc., Vineland, NJ) drawn from the
head only exposure apparatus, downstream from the primate’s
nares. Generator and impinger suspensions (pre- and post-bioaer-
osol) were serially diluted and plated on tryptic soy agar to deter-
mine bacterial titers (CFU/mL) and quadrant-streaked on Congo
Red agar to confirm culture pathogenicity by colony morphology.
Both samples were incubated at 28 C for 72 h prior to analysis.
The target particle size was 1–3 lm; particle size was determined
using a GRIMM Portable Aerosol Spectrometer Model 1.109
(GRIMM Aerosol Technik GmbH & Co. KG, Ainring, Germany). The
duration of the exposure was calculated based on the rate of bac-
teria delivery and the total volume of air inhaled by the animal
(target range was 3.5 ± 0.5 L). Inhaled aerosol dose (CFU inhaled)
was calculated after direct measurement of inhaled volume (from
plethysmography) and bacterial aerosol concentration was deter-
mined from the impinger sample. The calculation used the for-
mula: Dose = (C  V), where C is the concentration of viable
pathogen in the exposure atmosphere, and V is the volume inhaled.
2.4. Plazomicin pharmacokinetics (PK) study in healthy animals
and dose justification for efficacy study
The intent of the efficacy studies was to determine if the current
clinical plazomicin dose is effective in the AGM model. Because of
differences in clearing organ function per unit body weight across
species,19 higher doses are generally required for smaller animals
to generate the same drug exposure. To address this, a repeat-dose
PK study was conducted in compliance with the FDA 21 CFR Part
58 Good Laboratory Practice (GLP).20 Eight healthy AGMs under-
went a complete physical exam and were randomized (stratified
by body weight) to two dose groups receiving total daily pla-
zomicin doses of 25 or 35 mg/kg/day. Animals were administered
plazomicin by IV infusion twice daily (target interval between
AM and PM infusions was 12 h) for 7 consecutive days. Blood
was collected at multiple time points during each of the 7 days
of dosing and analyzed for plazomicin concentration by LC–MS/
MS. PK analysis was performed using WinNonLin Professional,
Version 5.0.1, model 202. Additional blood was collected each
morning prior to dose administration for creatinine values on days
1–7 and analyzed using the Hitachi Modular Analytics Clinical
Chemistry System (Roche Diagnostics, Indianapolis, IN).
2.5. Drug administration
Sixty-four AGMs were randomized into six exposure cohorts
using Microsoft Excel’s (Microsoft, Redmond, WA) random num-
ber generator. Exposure order was randomly assigned per gender
using Provantis (Instem LSS Ltd, Staffordshire, England) or
Microsoft Excel’s random number generator, alternating between
the sexes. Animals were assigned to treatment arms by exposure
order.
Treatment with plazomicin or placebo (saline for injection, the
diluent for plazomicin) was initiated within 6 h of the first
recorded sustained fever. For studies FY-105A and FY-105B, this
was defined as a temperature of >39 C sustained for 1 h. Based
on the observation of variable baseline temperatures across ani-
mals in the first two studies, the fever definition was changed in
study FY-036A to an increase of 1.5 C over baseline sustained for
1 h. The baseline temperature was determined by averaging each
individual animal’s temperature in hourly intervals (to account
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challenge.
Treatments were administered through the surgically
implanted catheter in the femoral vein via a syringe pump in a
total volume of 1 mL/kg (based on day 1 body weight), over
30 ± 5 min every 12 ± 1 h. To mimic the human PK of plazomicin
in the AGMs (e.g., ‘humanized’ once daily dosing), alternating dose
solutions that contained 90% and then 10% of the total daily dose
(6.25, 12.5 or 25 mg/kg), were administered.21,22 This was done
to correct for the more rapid clearance in AGMs compared to
humans and to more closely approximate the shape of the PK curve
and trough drug levels in human patients given a once-daily infu-
sion. A similar strategy was followed in the pivotal levofloxacin
plague studies.22 For each animal, the first two daily primary
(90%) dosages (dose 1 and 3) were administered 24–25 h apart. A
longer time interval (24–28 h) was allowed between dose 3 and
5 to enable synchronization of animal treatments.
2.6. Clinical observations
Pre-exposure clinical observations were performed with special
attention to normal behavior, presentation, and food intake to pro-
vide baselines for each individual animal post-exposure. For up to
30 days following challenge, Provantis-defined clinical observa-
tions were performed by LRRI according to standard operating pro-
cedures,23 noting respiratory distress, neurological symptoms,
provoked and unprovoked behavior, food intake and body weight
trends, appearance/posture and gastrointestinal/urogenital
abnormalities.
Between 2 and 6 days post-exposure, animals had an increased
likelihood of reaching a moribund state. Therefore, during that per-
iod, animals were monitored via telemetry for changes in body
temperature, respiratory rate and heart rate at least every 4–6 h.
During the treatment phase, observations were timed to occur dur-
ing the test article infusion periods. For the remainder of the study,
clinical observations were performed twice daily.
2.7. Telemetry observations
Body temperature (abdominal core temperature; C), respira-
tory rate (thoracic cavity movement; breaths/min), and heart rate
(derived from the R–R interval via the electrocardiogram leads in
a Lead II configuration; beats per min) were continuously recorded
by implanted Konigsberg T34 telemetry devices (Konigsberg
Instruments, Inc., Pasadena, CA). Telemetry data were averaged
(derived) into 5-min values for real time data evaluation during
the in-life phase of the study. During the clinically critical phase
of the study (days 2–6), where the onset of infection (febrile status)
and likelihood of reaching euthanasia criteria is highest, telemetry
data were assessed every 4–6 h. In one instance, a telemetry failure
occurred. For this animal, a rectal temperature was used to deter-
mine febrile state.
2.8. Clinical chemistry, hematology, bacteremia determination
and pharmacokinetics
Blood was drawn from animals for clinical chemistry, hematol-
ogy and quantitative bacteremia determination pre-challenge, pre-
first treatment with placebo or plazomicin, prior to fifth and ninth
or nineteenth treatment and prior to euthanasia. For clinical chem-
istry, blood was collected into a serum separator tube, allowed to
clot and then centrifuged for at least 10 min at 2500–3000g at
ambient temperature. Serum parameters were determined using
a cobas c311 chemistry analyzer (Roche Diagnostics, Indianapolis,
IN). For hematology analysis, blood was collected into a tube con-
taining ethylenediaminetetraacetic acid (EDTA) and a glass slidesmear was made. Hematology parameters were determined using
an Advia120 (Bayer Corporation, Diagnostic Division, Tarrytown,
NY).
To determine bacterial load, blood (target volume 1.2–1.5 mL)
was collected into a tube containing EDTA, and serial dilutions of
the sample were plated. The remaining undiluted sample (up to
1 mL) was plated on multiple plates (maximum volume of
200 lL per 100 mm plate) to achieve a detection limit of approxi-
mately 1 CFU/mL.
To determine plazomicin levels, blood (target volume 6 1 mL)
was collected into K2EDTA tubes and centrifuged (2500–3000g
at ambient temperature) to separate plasma. The plasma was cen-
trifuge-filtered through a 0.2 lm Nanosep MF centrifugal filter
(Pall Corp., East Hills, NY) at 13,000g for P20 min to sterilize
the plasma samples for subsequent removal from the ABSL3 facil-
ity for analysis. A 10% aliquot of each sample was cultured to con-
firm sterility. The remainder of the sample was stored frozen at
70 ± 10 C until sterility testing was completed and then shipped
to Alturas Analytics (Moscow, ID) for HPLC/MS/MS analysis. Phar-
macokinetic samples were drawn from placebo control animals
on day 1 only at 610 min after the end of the primary infusion
(peak level). Plazomicin-treated animals were tested pre-dose (col-
lected 630 min prior to the primary infusion; trough) and 610 min
after the end of the primary infusion (peak level) on treatment
days 1, 2, 3, 5 and additionally, for long-duration treatment groups,
day 7 and 10.2.9. Pathology and cause of death
Moribund or study end (28–30 days post-challenge) animals
were anesthetized with an intramuscular injection of P10 mg/kg
ketamine and euthanized by IV administration of 87 mg/kg pento-
barbital and 11 mg/kg phenytoin. Observation thresholds for
euthanasia included temperature >1.5 C above baseline (‘fever’)
followed by a consistent decline to >1.5 C below baseline, heart
rate >200 beats/min or higher for >24 h, which may or may not
be followed by a rapid decline, deep labored breaths with obvious
excessive work of breathing; >60 respirations/min for >24 h with
this breathing pattern, and physical observations (seizures [pro-
longed (>10 min) or recurrent (>3 instances of <10 min], or too
weak to climb onto perch or falling off perch, or constant hunched
posture and unresponsive to stimulation and refusal to eat any
offered food >48 h). The cause of death for each animal was estab-
lished by a board certified veterinary pathologist. Samples of
selected tissues (lung, liver, spleen, tracheobronchial lymph nodes,
kidney, brain, heart and any observed gross lesions) were taken at
necropsy, weighed and analyzed for the presence of Y. pestis by
quantitative culture. Tissue sections were fixed in 10% neutral-buf-
fered formalin, embedded in paraffin, processed by routine histo-
logical methods and stained with hematoxylin. Slides were
evaluated by a qualified veterinary pathologist.
In study FY-036, Y. pestis was collected from the tissues of ani-
mals that did not survive until study end and suspended in cry-
omedium (brain heart infusion broth + 20% glycerol) and stored
at 80 ± 10 C for plazomicin MIC determination. No bacteria were
detected at study termination (day 28–30 post-challenge) in any
animal across the three studies.3. Results
3.1. Plazomicin Pharmacokinetics (PK) in healthy animals
Plazomicin PK parameters are summarized in Table 1, and were
similar on day 1 and 7. One female AGM in the 25 mg/kg cohort
had a significantly lower AUC24 on day 1 (116 mg/L  h) compared
Table 1
Pharmacokinetics of plazomicin and serum creatinine levels in 8 healthy AGMs – day 1 versus day 7
Dose group Day Cmax (mg/L) AUC24 (mg/L * h) T1/2 (h) CL (L/h/kg) Serum creatinine (mg/dL) Vss (L/kg) Human equivalent dosea (mg/kg)
25 mg/kg 1 96 ± 32 185 ± 65 1.8 ± 0.1 0.13 ± 0.05 0.55 ± 0.14 0.33 ± 0.14 12
7 106 ± 15 208 ± 45 1.8 ± 0.1 0.11 ± 0.02 0.55 ± 0.13 0.36 ± 0.08
35 mg/kg 1 176 ± 24 306 ± 35 1.7 ± 0.1 0.10 ± 0.01 0.60 ± 0.05 0.26 ± 0.04 18
7 185 ± 13 319 ± 45 1.7 ± 0.1 0.10 ± 0.01 0.60 ± 0.13 0.31 ± 0.03
All values shown are median ± the standard deviation.
a Based on AUC24 and Cmax, the estimated dose equivalent to generate the same exposure in humans AUC24, area under the concentration time curve from time zero to 24 h;
CL, systemic clearance; Cmax, maximum plasma drug concentration; T1/2, elimination half-life; Vss, steady-state volume of distribution.
0.1
1.0
10.0
100.0
1000.0
0 4 8 12 16 20 24
Pl
az
om
ic
in
 C
on
ce
nt
ra
o
n 
(m
g/
L)
Time from ﬁrst Infusion start (h)
Day 1 - healthy
Day 7 - healthy
Day 1 - Infected (mean)
Day 3 - Infected (mean)
Day 10 - Infected (mean)
Figure 3. Healthy versus Y. pestis-infected AGM PK. Mean ± standard deviation
from four healthy AGMs administered 25 mg/kg plazomicin for 7 days (day 1 vs.
day 7 plotted as separate series). PK time points from day 1, 3 and 10 of dosing from
six Y. pestis-infected AGMs administered 25 mg/kg plazomicin for 10 days.
0
50
100
150
200
250
300
350
0 20 40 60 80 100
In
ha
le
d 
Ex
po
su
re
 (L
D5
0s
)
Time to Fever (h)
FY-105a
FY-105B
FY-036A
Figure 4a. Time to fever versus aerosol exposure in placebo- and plazomicin-
treated animals. Series represent the three separate studies.
0
50
100
150
200
250
300
350
0 20 40 60 80 100 120 140
In
ha
le
d 
Ex
po
su
re
 (L
D5
0s
)
Time to Death (h)
FY-105a
FY-105B
FY-036A
Figure 4b. Time to death versus aerosol exposure in placebo-treated animals.
Series represent the three separate studies.
W. M. Mega et al. / Bioorg. Med. Chem. 24 (2016) 6429–6439 6433to the other animals, reducing the mean median AUC24 from 215 to
185 mg/L  h. The day 7 AUC24 for this animal was also low but
was more in line with values from other animals, reducing the
median AUC24 from 220 to 208 mg/L  h. There is no obvious phys-
iological explanation for the lower exposure in this AGM based on
review of available health history and other covariates, although
she had the lowest bodyweight at study start. Serum creatinine
levels for each individual animal were either unchanged or
dropped by 0.1 mg/dL from day 1 to day 7.
The PK data indicate that to generate a median AUC24 similar to
15 mg/kg plazomicin in humans, the dose is approximately 31 mg/
kg/day in AGMs. We proceeded to efficacy studies with 25 mg/kg
as the top dose with the intention of slightly under-dosing (by
approximately 20%) in this model. By doing this, we increased
the probability of a high (P90%) pharmacokinetic/pharmacody-
namic (PK/PD) target attainment in future analyses when PK vari-
ability in critically ill patients24–26 will be considered.
3.2. Comparison of plazomicin PK in healthy versus infected
animals
In general, plazomicin PK was similar in Y. pestis-infected
AGMs compared to healthy animals. A representative dataset of
the six animals from study FY-105A administered the 25 mg/kg
daily dose compared to the results from healthy animals is shown
in Figure 3.
3.3. Time to fever/death does not correlate with increased
aerosol exposure in the range tested
Across the 64 animals, the inhaled bacteria exposures ranged
from 15 to 331 times LD50 (target was 100 ± 50 LD50). Fourteen ani-
mals fell outside the upper target range and six animals fell outside
the lower target range. Study FY-105a in general had higher
inhaled exposures but disease progression was similar to the other
studies. There was no correlation between inhaled exposure and
time to fever within the range tested (Fig. 4a). This is not particu-
larly surprising given the rapid (1.5 h) division time of Y. pestis
in vivo27 relative to the time to fever (48–72 h); small differences
in starting bacterial population are quickly erased. All six animals
that received challenge burdens lower than the intended target
(15–48 times the LD50) recorded a fever within the range of the
other animals (60.2–74.9 h) and all six were confirmed positive
for bacteremia before they were placed on therapy.
Similar to time to fever, there was no correlation between aero-
sol exposure and time to death in placebo-treated animals
(Fig. 4b). The time from fever to death was more consistent than
the association of either time to fever or time to death with inhaled
bacterial exposure (Fig. 4c), indicating that while the level of initial
bacterial exposure does not necessarily correlate with disease pro-
gression in the early stages of infection, once fever is established,
time to death from onset of fever is more consistent
(44.5 ± 12 h). Therefore, within the aerosol exposure range tested
(15–331 LD50) disease progression is highly consistent.
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Figure 4c. Time to fever versus time to death in placebo-treated animals. Series
represent the three separate studies.
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bacteremic, using fever as a surrogate marker. Of the 64 animals
across all studies, 60 were confirmed to have been bacteremic prior
to treatment, supporting the use of fever as a good indicator of bac-
teremia in this model. One sample was not evaluable (animal
B6436), although this animal eventually succumbed to the disease,
indicating that it was infected. Animals 7972, 7643 and 7908 had
no detectable bacteria in their blood prior to treatment initiation,
were treated with plazomicin, and survived to study end. Two of
these animals were in the 25 mg/kg, 10-day duration treatment
group and the third was in the 12.5 mg/kg, 10-day duration treat-
ment group. All three animals received an LD50 exposure within
the target range. At 28-day necropsy, all three animals had
histopathological evidence of a prior infection with resolving inter-
stitial and bronchiolar mononuclear cell infiltrations in all lung
lobes and additional evidence of substantial local challenge infec-
tion that had resolved (see below). It remains unclear whether
these three animals gave false-negative blood cultures or whether
they were truly not bacteremic at the time of treatment initiation.
3.4. Disease progression of placebo-treated animals
In total, across the six aerosol exposure cohorts, there were 12
placebo-treated animals. Y. pestis challenge doses ranged from
54–198 LD50 in these animals and the median time to fever was
59.3 h. Placebo infusions were initiated 0.5–5.9 h post establish-
ment of fever. All blood samples drawn prior to the first placebo
infusion were positive for bacteremia with a median bacterial den-
sity of 1.5  104 CFU/mL. All placebo-treated animals succumbed
to the disease within 71–129 h post-aerosol challenge. The range
of survival times between placebo infusion start and death was
17–61 h, therefore some animals started therapy <24 h before
death, illustrating an advanced state of decline when therapy
was initiated.
Five animals met moribund criteria (71–120 h post-aerosol
exposure) and were euthanized while the other seven died (88–
129 h post-aerosol exposure) prior to meeting the pre-defined
euthanasia criteria. At time of death, extremely high densities of
Y. pestis were observed in all tissues tested (Table 2). The median
bacterial burdens in lung, spleen, liver, kidney and tracheo-
bronchial lymph nodes were 7.7  108, 1.6  109, 5.1  108,
7.1  107 and 7.7  109 CFU/g of tissue, respectively. Due to gross
pathological findings early in the first study, the protocol was
amended to include analysis of heart and brain tissues, and median
bacterial burdens in these tissues were 2.6  107 CFU/g and
1.9  106 CFU/g, respectively.
Comparison of a selected subset of clinical chemistry and hema-
tology parameters at baseline and time of death in those animals inwhom samples were available (Table 3) revealed multiple organ
failure with declining kidney function (increases in blood urea
nitrogen and serum creatinine) and liver function (increases in ala-
nine aminotransferase and gamma glutamyl-transferase). Signifi-
cant increases in serum lactate dehydrogenase and white blood
cell count indicate extensive tissue damage and inflammation.
Based on pathological findings, the assigned cause of death for
11 of the 12 placebo-treated animals was sepsis with or without
direct contribution of concurrent pneumonia. The cause of death
in the twelfth animal, B6394, was sepsis exacerbated by aspiration
pneumonia, which was attributed to overall worsening condition
and sepsis.3.5. Overall survival of plazomicin-treated animals
Relative to placebo-treated animals, all animals receiving pla-
zomicin, regardless of dose or duration of therapy, showed signif-
icantly increased survival time (Figs. 5a5b and Table 4). Among
the plazomicin-treated groups, survival to study end improved
with both increased dose of plazomicin as well as increased dura-
tion of therapy. Shorter duration therapy with 25 mg/kg pla-
zomicin improved survival to study end to 69%. The short
duration 12.5 mg/kg and 6.25 mg/kg doses only protected 33%
and 17% of animals, respectively, and were the only dose/duration
regimens that did not provide a statistically significant improve-
ment in survival to study end relative to placebo control, although
they did significantly extend survival time. Across all studies, three
animals died very early while still on therapy (described in detail
below); therefore they are not valid data points to include in a
comparison of therapy durations since they did not complete treat-
ment. Removing those animals revealed that for the high-dose
group, results were similar for 5- versus 10-day treatment but still
trended toward inferiority for the mid- and low-dose group
(Table 5). The highest survival rates were observed with 10 days
of dosing, with even the lowest dose of plazomicin providing sig-
nificant benefit.3.6. Disease progression of plazomicin-treated animals
3.6.1. Deaths on therapy
Three animals died while receiving plazomicin therapy. In the
25 mg/kg 5-day treatment group, animals B6469 and B6436 suc-
cumbed 57 and 14 h after initiating therapy, respectively. One
12.5 mg/kg 5-day treatment animal, B6873, also succumbed after
receiving all but one of its infusions.
Animal B6436, which only received a single humanized dose of
plazomicin, had moderate to severe, locally extensive, sublobar
and lobar acute inflammation in multiple lung lobes and mild,
locally extensive acute inflammation in the right middle lobe.
There was pronounced hemorrhage with alveolar edema and/or
fibrin exudate in some areas and associated destruction of the alve-
olar walls. Viable bacteria were not detected by histologic exami-
nation in areas of acute inflammation or in blood vessels or
lymphatics. High power magnification and image enlargement
detected pale staining bacteria-like forms that may have been
non-viable bacteria. Low bacterial numbers (103 CFU/g) were cul-
tured from lung tissue samples compared to higher numbers (108–
109 CFU/g) found in the lungs of placebo-treated animals (Table 6).
Taken together, these findings indicate highly effective bacterial
killing by plazomicin. Despite the large reduction in viable bacte-
ria, however, lung damage was extensive and was considered the
primary cause of death. Because the placebo-treated animals were
succumbing at the same time as this animal, we are able to observe
the impact of a single therapeutic dose of plazomicin on bacterial
burden; compared to the median value of the placebo-treated
Table 2
Bacterial burden at time of death in placebo-treated animals
Animal Lung CFU/g CFU/mL
Spleen Liver Kidney TBLNa Heart Brain Blood
B6077 5.9  108 6.1  109 7.2  108 1.2  108 3.6  109 Ndb Nd Nsc
B6397 6.5  109 2.2  1010 4.2  108 3.0  108 8.7  109 5.5  108 1.6  107 Ns
B6343 1.7  108 9.3  109 2.4  1010 1.2  109 2.2  107 2.1  109 3.7  109 3.0  109
B6394 5.7  108 1.4  109 2.2  107 3.1  106 1.2  1010 4.4  105 7.4  104 3.7  106
B6560 3.0  109 2.0  108 9.4  108 1.5  107 9.7  109 5.9  107 4.6  105 1.2  107
C2038 7.4  108 1.9  107 1.4  109 1.4  109 1.4  1010 1.2  107 1.9  105 Ns
B6858 1.7  109 1.7  109 7.2  107 7.1  107 5.3  1010 9.8  107 1.9  106 8.0  106
B6995 2.8  109 9.4  108 9.2  107 1.1  107 1.4  1010 9.4  105 4.7  104 Ns
7514 7.9  108 1.9  109 9.0  108 1.7  108 4.6  109 2.6  107 5.3  107 Ns
8044 3.2  109 1.5  109 2.1  108 4.8  107 3.4  108 1.7  107 3.7  106 Ns
8058 2.7  109 1.4  1010 6.1  108 7.0  107 6.7  109 8.5  107 1.2  107 5.2  108
7694 5.8  109 3.3  108 1.7  108 5.4  106 1.1  109 1.7  106 1.6  105 Ns
a Tracheobronchial lymph nodes.
b Nd – not determined. Samples were not obtained for this animal as the protocol was amended after gross observations were taken.
c Ns – no sample. Animal was found dead therefore terminal blood samples were not available.
Table 3
Clinical chemistry and hematology pre-study and at time of death
Animal BUNa (mg/dL) Creatinine (mg/dL) GGTb (IU/L) ALTc (IU/L) LDHd (IU/L) WBCe count
(103/lL)
Pre Terminal Pre Terminal Pre Terminal Pre Terminal Pre Terminal Pre Terminal
B6343 13 30 0.6 1.2 36 55 31 522 326 3890 4.1 33.5
B6394 19 46 0.5 1.4 96 220 40 686 539 6890 6.8 21.1
B6560 22 52 0.7 2.4 90 194 155 Ndf 465 Nd 9.1 47.4
B6858 19 41 0.8 2.2 45 112 27 90 209 2496 7.8 50.5
B6995 22 39 0.7 1.8 45 71 51 121 191 1824 6.0 23.4
8058 14 32 0.8 3.6 61 Nd 74 80 414 6510 5.7 45.4
7694 17 61 0.6 1.5 32 7 58 72 264 2525 8.4 10.8
a Blood urea nitrogen.
b Gamma glutamyl-transferase.
c Alanine aminotransferase.
d Lactate dehydrogenase.
e Total white blood cell count.
f Not determined – assay run failed quality control tests.
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examined, indicating significant bacterial killing with a single dose.
Animal B6469 was found dead on day 5 post challenge, after
2 days of plazomicin treatment. Unlike animal B6426, this animal
had only minimal to mild adverse findings in the lung. In contrast,
moderate macrophage and neutrophil infiltration was observed in
the meninges with associated hemorrhage, edema and blood vessel
congestion. Based on these findings, meningitis was consideredlikely the cause of death in this animal. Animal B6873 was ruled
moribund on day 7 post challenge, after 4 days of plazomicin treat-
ment. This animal had multiple locally extensive areas of subacute
inflammation in the left and right caudal lung lobes but other lobes
showed only minimal interstitial mononuclear cell infiltration.
These findings indicate that lung damage associated with aerosol
Table 4
Survival by treatment group and study cohort
Treatment group Study Survival to study end pa Survival time pb
FY-105A FY-105B FY-036A
Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Totals
Placebo 0/1 0/3 0/2 0/2 0/2 0/2 0/12 — —
25 mg/kg, 5 d 4/6 2/4 2/3 3/3 11/16 0.0003 <0.0001
12.5 mg/kg, 5 d 2/3 0/3 2/6 0.0980 0.0001
6.25 mg/kg, 5 d 1/3 0/3 1/6 0.3333 0.0001
25 mg/kg, 10 d 2/3 3/3 3/3 3/3 11/12 <0.0001 <0.0001
12.5 mg/kg, 10 d 3/3 3/3 6/6 <0.0001 0.0001
6.25 mg/kg, 10 d 2/3 3/3 5/6 0.0007 0.0001
a Two-sided Fisher’s exact test comparing treatment arm to placebo arm.
b Log-rank test comparing treatment arm to placebo arm, survival time through 28 days.
Table 5
Treatment duration effect on survival to study enda
Dose (mg/kg) Survival with plazomicin
treatment
pb
5 day 10 day
25 11/14 11/12 0.60
12.5 2/5 6/6 0.06
6.25 1/6 5/6 0.08
a Animals that received all scheduled plazomicin doses.
b Two-sided Fisher’s exact test comparing 10-day treatment arm to 5-day
treatment arm.
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animal B6469, neutrophil infiltration and bacteria were observed
in the meninges and choroid. Meningitis was considered the cause
of the moribund clinical signs observed in this animal. Thus,
animals B6469 and B6873 appeared to follow a similar progres-
sion. Both showed marked improvements in disease with respect
to bacterial burden in all tissues (5–9 log reduction relative to
median placebo control animals) as well as gross histopathological
findings, however, both succumbed to plague meningitis.Table 6
Bacterial burden at time of death in plazomicin-treated animals
Animal Cause of death Treatment arm CFU/g
Lung Spleen
Placebo (median) 7.7  108 1.6  109
B6436 Lung damageDOT 25 mg/kg, 5 d 4.4  10c BLDb
B6469 MeningitisDOT 25 mg/kg, 5 d 2.1  10b 4.6  10a
B6873 MeningitisDOT 12.5 mg/kg, 5 d 1.6  10c BLD
B6106 Meningitis 25 mg/kg, 5 d 1.9  10d 3.1  10c
B6872 CNSe infection 25 mg/kg, 5 d BLD BLD
B6127 Meningitis 25 mg/kg, 10 d BLD BLD
B6415 Pneumonia/ sepsis 25 mg/kg, 5 d 3.2  109 9.0  10d
C2083 Resurgence of pneumonia 12.5 mg/kg, 5 d 3.7  106 1.5  107
B6672 Resurgence of pneumonia 12.5 mg/kg, 5 d 9.2  109 2.5  10d
B6783 Resurgence of pneumonia 12.5 mg/kg, 5 d 2.8  109 1.0  10e
B6861 Pneumonia 6.25 mg/kg, 5 d 1.2  108 9.5  10d
C2149 Pneumonia 6.25 mg/kg, 5 d 1.0  109 3.0  10d
B6889 Pneumonia 6.25 mg/kg, 5 d 2.2  109 6.2  106
B6960 Pneumonia 6.25 mg/kg, 5 d 3.0  109 2.3  10d
B6988 Pneumonia 6.25 mg/kg, 5 d 3.2  108 1.7  10e
8047 Pneumonia 6.25 mg/kg, 10 d 6.6  109 1.9  10e
DOT – died while on therapy.
a Tracheobronchial lymph nodes.
b BLD – below limit of detection/no bacteria detected.
c Nd – not determined. Samples were not obtained for this animal as the protocol wa
d Ns – no sample. Animal was found dead therefore terminal blood samples were not
e CNS – central nervous system.3.6.2. Deaths post-therapy cessation
Thirteen animals died after completion of plazomicin therapy.
All but one of these deaths were in animals that received either
the lowest dose or short duration therapy. Ten of these 13 animals
had an assigned cause of death of pneumonia and most of those
animals were in the low- and mid-dose groups with short treat-
ment duration (Table 6). In these animals, terminal necropsy sug-
gested inadequate sterilization of the lungs that led to regrowth of
bacteria and re-establishment of disease as the cause for failure.
We considered two possible reasons for treatment failure: fail-
ure to eradicate initial infection and emergence of resistance. The
data more strongly favor failure to eradicate as the cause of treat-
ment failure because at 10 days’ duration, even the lowest dose
was highly effective compared to shorter course therapy at this
same dose. If emergence of resistance was the predominant cause
for failure, we would have expected increased doses, but not nec-
essarily longer durations of therapy, to play a major role in improv-
ing outcomes. To directly address the two hypotheses, we profiled
three Y. pestis isolates from the lung tissue of animal 08047 which
was given the low dose of plazomicin for 10 days and succumbed
on day 19 post infection. All three isolates had identical MICs com-
pared to the parent Colorado 92 strain (0.5 mg/L), supportingCFU/mL
Liver Kidney TBLNa Heart Brain Blood
5.2  108 7.1  107 7.7  109 2.6  107 1.9  106 1.2  107
BLD BLD 3.0  10b Ndc Nd BLD
BLD BLD BLD Nd Nd NSd
BLD BLD BLD BLD 4.4  10e BLD
9.5  10c 1.7  10c BLD BLD 6.4  107 4  10a
BLD BLD BLD BLD 4.1  106 BLD
4.4  10a BLD BLD 9.4  10a 3.9  10c BLD
2.0  106 1.5  10e 7.1  107 6.2  10e 3.9  10d NS
4.5  109 3.1  106 8.0  109 1.5  107 2.2  106 2.4  10e
7.6  10e 2.5  10d 8.3  106 2.9  10d 2.3  10c NS
8.4  106 7.6  10c 6.3  109 8.0  10c 3.3  10b 2.7  10b
1.6  10e 1.1  10d 1.2  108 1.6  10e 1.2  10e NS
1.0  106 1.6  10e 1.0  109 9.7  106 4.6  10d NS
2.2  107 1.1  106 3.6  109 1.0  106 8.0  10d 9.3  10e
3.8  10d 7.2  10c 1.6  107 1.2  106 BLD NS
1.7  10d 2.3  10e 6.6  106 4.5  106 1.1  10b 1.1  10b
1.3  106 3.2  10d 2.0  109 2.0  107 6.0  10d NS
s amended after gross observations were taken.
available.
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dose as the cause for treatment failure.
The three non-pneumonia deaths that occurred post-therapy
cessation were attributed to meningitis/central nervous system
infection (Table 6). In all cases, bacteria were observed in the brain
while marked reductions in bacterial burden were observed in
other tissues. Animal B6106 was an exception in that it had mod-
erate counts (104 CFU/g) in the lung suggesting that if the animal
did not succumb to the meningitis it may have suffered from a
resurgent pneumonia.
One of the meningitis-attributed deaths was animal B6127,
which was the lone death in the plazomicin high-dose/duration
group. This animal had a notable history in the study. Between
aerosol exposure and treatment, the animal’s implanted tempera-
ture probe failed and therefore an alternative temperature mea-
sure was employed. This potentially delayed therapy initiation
significantly, although it is difficult to know by how long.
Histopathological examination of this animal revealed it had
stomach ulcers and hematology findings that indicated stress con-
tributed to the outcome. The animal had weight loss from day 7
post-challenge, worsening from approximately day 14 and devel-
oped inappetence and dehydration, attributed, in retrospect to
worsening meningitis. Terminal serum chemistry showed elevated
blood urea nitrogen. The higher blood urea nitrogen taken together
with serum electrolyte abnormalities and moderate tubule damage
in the kidney by histologic examination suggested that the animal
had renal uremia with hyperchloremic metabolic acidosis and may
also have had prerenal uremia because of dehydration. These fac-
tors contributed to and exacerbated the outcome. Serum chemistry
physiologic and metabolic alterations in this animal may be
explained by both the kidney tubule damage and pathophysiologic
impairment associated with meningitis. Renal tubule alterations
were attributed to plazomicin administration and indicated tubule
toxicity (nephrosis). Therefore we hypothesize that the further
delayed treatment allowed for meningitis to establish as with
other animals mentioned above, however the downstream impact
was a more advanced state of disease prior to initiating therapy.
Fluid replacement therapy and dose adjustment for impaired renal
function, which would be reasonable clinical interventions, were
not designed as part of this study but may have improved the
outcome.
3.6.3. Surviving animals
Thirty-six plazomicin-treated animals survived through study
end. The majority (33/36) were either in the 10-day duration
groups (high-/mid-/low-dose) or the 5-day duration high-dose
group, supporting the importance of both dose and duration on a
successful outcome. All 36 animals had no detectable bacteria in
blood or any tissue tested. Serum chemistry and hematology
parameters returned to baseline for all animals. Results for the
25 mg/kg 10-day treatment group are shown in Table 7.
Histopathological examination of the survivors, in general,
revealed minimal to mild residual and resolving alterations in
the lung. Overall, histologic findings in the lung, at the organ level,
were considered non-adverse to minimally adverse. Evidence of
slightly lower efficacy of the 6.25 mg/kg 10-day regimen was evi-
dent due to liver inflammatory cell infiltrates in animals at sched-
uled necropsy. There were no alterations in organ weights in any
group. Residual and resolving kidney tubule atrophy alterations
in a subset of animals in the 25 mg/kg 10-day and 12.5 mg/kg
10-day groups were focal, multiple and minimal. Alterations were
considered non-adverse. They were considered possibly associated
with plazomicin administration, but a dose–response was not
observed. In fact, slightly more evident alterations in two animals
in the low 6.25 mg/kg 10-day group suggest that a more persistentY. pestis bacteremia and systemic infection contributed to the kid-
ney findings.
4. Discussion
Y. pestis is considered to be one of the most lethal possible bio-
weapons. There are only two FDA-approved agents for the treat-
ment of pneumonic plague and both share common resistance
mechanisms.6,7 This study demonstrated the efficacy of a new
antibiotic, plazomicin, in the treatment of lethal pneumonic plague
in a rigorous nonhuman primate model. All animals who received
placebo died, while 36 of 52 animals that received plazomicin sur-
vived until study end on day 28 post-exposure. Demonstration of
efficacy depended on both the dose of plazomicin and the duration
of treatment. In this work we defined the minimum dose and dura-
tion of plazomicin therapy required to successfully treat advanced
pneumonic plague in the most widely accepted model, the African
Green monkey. To ensure the model was sufficiently challenging,
animals were treated only when the pneumonia had progressed
to a systemic disease and bacteremia was confirmed in 60 of 64
animals tested using fever as a surrogate marker for systemic dis-
ease progression. In future pivotal studies, randomization to treat-
ment arms could be done post-fever detection and it would be
wise to slightly over-power each arm to accommodate the occa-
sional animal in which bacteremia is below detection limits.
This work provided a unique opportunity to study the efficacy
of plazomicin in a pre-clinical model that is more akin to human
infection than the models classically used to characterize antibiotic
efficacy. Classic pre-clinical efficacy studies rely on immunocom-
promised rodent models that mostly examine dose/effect relation-
ships in the absence of an appreciation for the host-pathogen
interaction.28 These models serve the field well in setting doses
for acute response (initial bacterial kill) but fall short in three crit-
ical, and interrelated, areas: (1) they do not test how the drug per-
forms in the presence of very high bacterial burdens where a large
resistant sub-population is likely to be present for many drugs; (2)
they do not test the impact of duration of therapy and (3) they fail
to examine physiologically critical organ and tissue types associ-
ated with the clinical manifestation of infection. For example, a
classic neutropenic mouse thigh model might examine 106–107
total bacteria in an isolated site (thigh tissue), whereas in this
study bacterial burdens in excess of 1011 total organisms are
achieved in a multi-organ infection setting. There are few opportu-
nities in in vivo systems to challenge a drug under these conditions
short of actual human clinical trials. Furthermore, in human trials
of severe infections, the need for combination therapy to match
current standards of care complicates interpretation. Therefore
the ability to study a drug as a monotherapy under challenging
infection conditions may be unique to these types of models.
Based on overall survival, the minimum therapeutic daily dose
of plazomicin was 6.25 mg/kg when given for sufficient duration.
This dose is equivalent to 3 mg/kg in humans, 5-fold below the
current clinically proposed dose. We demonstrated the importance
of therapy duration, showing a trend toward superiority with 10
compared to 5 days of therapy at the mid- and low-dose levels.
High-dose therapy (25 mg/kg, 12 mg/kg equivalent dose in
humans), even at short (5-day) duration, was able to provide sig-
nificant protection, which supports claims in the literature that if
therapy intensity is sufficiently high, shorter courses of treatment
can be successful.29 This may be particularly relevant for an extre-
mely virulent agent like Y. pestis where a small bacterial exposure
leads to disease and thus even a small remaining reservoir of viable
bacteria post-treatment could lead to disease relapse. With an
agent such as plazomicin that is rapidly bactericidal,30 protection
can be achieved provided the dose is sufficiently high as
Table 7
Serum chemistry and hematology results for survivors treated with 25 mg/kg plazomicin for 10 days
Animal BUNa (mg/dL) Creatinine (mg/dL) GGTb (IU/L) ALTc (IU/L) LDHd (IU/L) WBCe Count (103/
lL)
Pre Terminal Pre Terminal Pre Terminal Pre Terminal Pre Terminal Pre Terminal
B5994 15 18 0.6 0.5 35 38 62 46 364 403 8.0 4.5
B6408 22 20 0.5 0.4 53 56 109 94 249 304 6.9 5.5
B6291 24 21 0.6 0.5 77 102 47 68 212 259 12.0 5.9
B6140 24 27 0.8 0.7 55 39 180 71 290 379 6.8 7.2
B6428 16 26 0.8 0.6 31 27 83 60 238 299 6.2 6.0
7972 13 24 0.8 0.7 46 38 30 36 381 398 6.9 7.6
7929 15 17 1.0 0.9 44 16 63 41 653 496 10.9 8.5
8067 13 21 0.8 0.8 40 26 45 50 287 478 10.0 9.4
7643 16 19 0.5 0.4 44 35 53 43 278 606 6.1 5.7
7337 15 18 0.7 0.5 67 63 55 44 310 469 7.5 5.0
7653 22 26 0.6 0.8 37 27 50 48 319 426 7.5 5.8
a Blood urea nitrogen.
b Gamma glutamyl-transferase.
c Alanine aminotransferase.
d Lactate dehydrogenase.
e Total white blood cell count.
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These findings suggest that relatively short course therapy with
the current clinical dose of plazomicin may be an effective treat-
ment for human plague.
In our studies, efforts were made to minimize the number of
animals receiving placebo. Given the possible variance in animal
health history, the complexity of generating the bioaerosols, and
the paucity of available data regarding this animal model (our
studies were designed and initiated in 2010 prior to the public
release of the levofloxacin and moxifloxacin studies), we felt the
inclusion of two males and two females per study was imperative.
With the large body of data now available from our studies and
those of the fluoroquinolones regarding the natural history of pla-
cebo-treated pneumonic plague in AGMs, we suggest that future
studies in this model consider relying on this historical dataset
as a control rather than utilize additional placebo-treated animals.
Given the absence of robust human clinical efficacy data in this
indication, study of an adequate dose response in animal models is
essential. This mandates dosing to levels that demonstrate com-
promised/reduced efficacy and/or decreased survival rates, so that
better PK/PD relationships can be established. For the two cur-
rently approved drugs, levofloxacin and moxifloxacin, no dose
response information has been communicated, therefore it is diffi-
cult to predict and at what exposure (or Y. pestis MIC) efficacy
would be compromised. This is a critical knowledge gap because
the PK of these drugs25,31 is altered dramatically in critically ill
patients.24–26,32 Our current analysis supports that the plazomicin
exposures in Y. pestis-infected AGMs are similar to those observed
in healthy AGMs. Plazomicin PK data from critically-ill patients
infected with CRE will be included in the plazomicin population
PK model and this information may be used to inform recom-
mended dose/exposure for future pneumonic plague pivotal
studies.
Both levofloxacin and moxifloxacin provided impressive benefit
in the AGM model, with 92% and 100% survival at the one dose
level tested, administered for a 10-day duration.6,11,12 Plazomicin
achieved similar efficacy, resulting in 92%, 100% and 83% survival
of animals at the high, mid- and low doses administered for
10 days. During the course of our studies, we identified meningitis
as a significant contributor to treatment failure. The observation of
plague meningitis in this model was unexpected. Plague meningi-
tis is rare in humans (approximately 6% of cases)33 and has not yet
been reported by others in the AGM infection model, including in
the fluoroquinolone studies. Fluoroquinolones have higher pene-
tration into cerebral spinal fluid than aminoglycosides34–36 andtherefore may have superior efficacy against plague meningitis.
Our data and the published levofloxacin and moxifloxacin studies
support this. It is important to highlight that although the fluoro-
quinolones are able to reach therapeutic levels in the cerebral
spinal fluid, they are at much lower concentrations than in the
bloodstream.36 Therefore it is even more critical to understand
the exposures at which efficacy of these drugs begins to wane, to
inform when to deploy other assistive countermeasures such as
chloramphenicol, which is the recommended treatment when pla-
gue meningitis is suspected.33
Findings of plague meningitis motivated us to modify the study
protocols going forward to sample brain tissue in greater detail.
From this we determined that Y. pestis are readily detected in the
brains of most animals at time of death. For placebo-treated ani-
mals we hypothesize that due to the rapid progression of pneumo-
nia and sepsis, meningitis is never able to fully develop as an
attributable cause of death. We further hypothesize that in animals
where therapy is initiated too late and/or where inadequate sys-
temic bacterial eradication occurs, Y. pestis is able to establish an
infection in the central nervous system where the majority of
antibiotics, including aminoglycosides like plazomicin, have lim-
ited exposure. This in turn, leaves bacterial proliferation unchecked
locally, leading to development of meningitis and potentially serv-
ing as a reservoir for bacterial spread once therapy is stopped.
In all other tissues, including the lung, plazomicin was highly
effective. The efficacy of aminoglycosides in pneumonia has been
questioned in the literature; hypotheses such as poor lung penetra-
tion, chelation by lysed white blood cell DNA, and the acidic envi-
ronment in the lung have been proposed as reasons for reduced
efficacy.29 However, little clinical or pre-clinical primary data are
available to support these claims. Our studies of plazomicin, and
the legacy aminoglycosides, support that they have excellent activ-
ity in multiple preclinical lung infection models.27,37–40 In fact,
prior to the approval of levofloxacin and moxifloxacin, gentamicin
and streptomycin were the primary recommended therapies for
the treatment of plague.3
A potential explanation for the discord could be that early
aminoglycoside usage employed very low, sub-optimal doses and
dosing schedules. For example in the 1970s and 1980s, gentamicin
was dosed 1 mg/kg every 8 h compared to modern optimized
dosing of 5–7 mg/kg once daily.29,41 Two published comparative
studies of aztreonam (a monobactam antibiotic) and the aminogly-
coside tobramycin concluded that tobramycin is inferior to aztre-
onam for the treatment of Gram-negative pneumonia.42,43 A third
study published in the same timeframe demonstrates equivalence
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between 3000 and 8000 mg per day while the tobramycin dose
was 80 mg every 8 h. Given the current understanding that once
daily dosing of aminoglycosides is superior both in terms of safety
and efficacy,29,41,45 these prior clinical observations may be
misleading.
In addition to under-dosing, aminoglycoside susceptibility
breakpoints were (and in some cases still are) too high based on
our modern understanding of the PK/PD relationship of the class.
Based on a thorough evaluation of PK–PD target attainment analy-
ses, and available clinical outcomes data, USCAST has recently pro-
posed lowering the susceptibility breakpoints for all currently
marketed aminoglycosides, (USCast002 v1.1, www.uscast.org),
supporting the notion that historical breakpoints are too high.
The combination of these factors enabled legacy aminoglycoside
use with sub-optimal doses, and for organisms whose MICs were
so high that unacceptably low rates of target attainment would
be expected, especially in the case of the lung pathogen Pseu-
domonas aeruginosa.
In conclusion, plazomicin represents a valuable addition to the
armamentarium against pneumonic plague. The fluoroquinolones
are a highly attractive countermeasure given the availability of
both IV and oral formulations and their superior cerebral spinal
fluid penetration. However, additional antibiotic classes with
diverse mechanisms of action are required to prevent over-reliance
on a single class to which resistance may be easily bred. Based on
the data generated here, the addition of plazomicin to the current
countermeasure options is warranted and these studies will inform
an optimal design for pivotal trials in this indication.
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